Further defining the genetic architecture of Alzheimer's disease
Lead Research Organisation:
Cardiff University
Department Name: School of Medicine
Abstract
Alzheimer's disease is a common debilitating disorder which affects individuals, families and communities. Just under half a million people have Alzheimer's disease (AD) in the UK with an estimated cost of £23 billion per year. It is also estimated that the numbers with AD will double in the next generation. It is vital we understand what causes this disease and develop therapies to prevent, delay and treat it. Finding genes which affect the development of AD is an important means to pinpoint processes that are going wrong and contributing to the death of brain cells, which characterises this disease and underlies the symptoms of memory loss and general cognitive degeneration. Over the last 25 years approximately a quarter of the genetic contributors to disease have been identified and our group have played a pivotal role in this and have recently discovered 8 of the 10 common risk variants for AD. This has made us re-think some of our ideas about the specific processes which contribute to disease. These genes cluster together to form groups, implicating processes like our immune response, how we process lipids like cholesterol in the brain and a specific process called endocytosis, which brings large molecules into cells and affects their transport within cells, such as neurons. But over half the genetic contribution to disease is yet to be found. We propose a programme of research which builds on our current strengths, focusing on identifying rare genetic variants of moderate to strong effect observed in the coding regions of genes. We will perform a large, powerful study in which we compare 300,000 DNA variants from throughout the human genome, in 20,000 AD cases and 49,000 controls. Through sample collection and collaboration, we will enrich our clinical samples to include 1000 individuals with early onset AD. This group are more likely to have rare genetic changes of moderate to large effect on their development of disease. This experiment has an excellent chance of identifying new risk genes for AD and producing targets better suited to model disease in human cells and produce new therapeutics. We will also facilitate future research by producing a bio-bank of cell lines suitable for human modelling of disease using the latest stem cell technology (inducible pluripotent stem cells: iPSC) and making this available to the research community and pharmaceutical companies.
Technical Summary
Approximately half a million people have Alzheimer's disease (AD) in the UK, incurring an annual care cost of £23 billion. 35 million have dementia world-wide and it is estimated that these numbers will double by 2040. Identifying genes that affect the development of AD is important in pin-pointing potential disease mechanisms, testing new therapeutics and in predicting individual risk of disease development. Our programme of research will focus on identifying rare, exonic susceptibility variants of moderate/strong effect, using novel, powerful, genome-wide approaches and extended and enriched clinical samples. We will undertake a case-control association study comprising 20,000 AD cases and 49,000 controls focusing on coding regions throughout the genome, using the Illumina exome chip. We will also collect a sample of 500 cases with early-onset AD (EOAD), an uncommon form of the disease (<5% cases) that manifests before the age of 65, and in which heritability is especially high (92-100%). We will sequence the exomes of the 500 EOAD individuals and analyse them together with 500 EOAD exomes available to us through collaboration. Susceptibility variants identified will be replicated in an independent sample of 10,000 AD cases and 10,000 controls. We aim to detect rare variants of larger effect than those observed for common susceptibility variants; these effects should prove easier to model and will facilitate the further understanding of disease mechanisms and the development of new therapeutics. We will combine all genetic data we have generated to extend and develop complex analyses including pathway analysis, sub-phenotypic analysis and cross-disease analysis. Finally, we will establish and extend research resources such as DNA and additional sample banking from all EOAD cases collected, and iPSC programmable cell lines from 50 EOAD cases to facilitate functional analyses. This resource will be made available to research and pharmaceutical communities.
Planned Impact
The ultimate aim of this research is to build a better understanding of the causes of Alzheimer's disease and in so doing, provide a platform for the development of targeted treatments and preventions. Thus the main potential beneficiaries are those with the disease and those at risk of developing the disease. AD has a high impact on society. The cost of caring for individuals with the disease is around £23billion per year, with a substantial component due to the social cost of funding practical care and the cost to society of losing skilled family members from the workforce, who care for relatives directly. Thus AD affects more than just the individuals diagnosed. It affects the family and the wider community. We know that the number of people with AD will double in the next generation, so this problem is getting worse. The timescale on identifying new drug targets and translating this into the clinic is typically 10-15 years.
Another potential impact of our research is in characterising individual risk profiles, which could be useful in improving the efficiency of clinical trials. For example, a particular drug under trial could be more beneficial for those with one type of risk profile compared to others. Therefore, defining the variation in these profiles could aid more efficient clinical trials, resulting in increased numbers and better, targeted drugs coming to clinic. This could potentially have a considerable economic impact for the pharmaceutical sector. Most drugs fail to get through clinical trials, producing an enormous cost burden for pharmaceutical companies. We are working with pharmaceutical and other commercial companies to produce a test of genetic risk for use in clinical trials and are confident that this could be commercially available in the next couple of years.
As we further define the genetic architecture of AD, predicting one's risk of developing disease will become a more realistic outcome. Currently, genetic testing is only helpful for those with known autosomal dominant mutations. This programme is likely to result in several new variants of moderate to strong effect, which may also be used to predict disease in others. The timeline for this impact would be within the next 5 years.
Current animal and cellular models of AD have major limitations. This programme aims to identify genetic variants that have moderate to strong individual effects on disease development. Not only will these provide better animal models than the common risk variants identified so far, but will allow multiple genes to influence models, which may better reflect essential disease components. Currently, most mouse models based upon known disease mutations do not recapitulate the full range of disease symptoms. As we discover more genuine disease causing/risk variants, our ability to produce more realistic disease models will improve. This is likely to have significant impact on the success of commercial testing of new drugs by providing more accurate models. Mouse models could be available within a year of discovery and will be facilitated by our current funded collaborations- Neuromouse funded by the MRC.
In addition, iPSC models that reflect specific genetic risk profiles will be available to the research and commercial communities, directly from this research. This will provide relevant human cellular models to facilitate translation and be available during the course of the grant.
We also aim to identify genes that affect symptoms/characteristics of AD, such as psychosis, depression and rate of decline, which again can be used to target specific disease mechanisms through drug therapy. Similarly, we will test for common disease variants across diseases such as ALS, PD, cardiovascular disease and diabetes. These findings may be used to support drug development for the prevention of or treatment for individuals with or at risk of developing a broad range of diseases. Timelines of 10-15 years, as described above.
Another potential impact of our research is in characterising individual risk profiles, which could be useful in improving the efficiency of clinical trials. For example, a particular drug under trial could be more beneficial for those with one type of risk profile compared to others. Therefore, defining the variation in these profiles could aid more efficient clinical trials, resulting in increased numbers and better, targeted drugs coming to clinic. This could potentially have a considerable economic impact for the pharmaceutical sector. Most drugs fail to get through clinical trials, producing an enormous cost burden for pharmaceutical companies. We are working with pharmaceutical and other commercial companies to produce a test of genetic risk for use in clinical trials and are confident that this could be commercially available in the next couple of years.
As we further define the genetic architecture of AD, predicting one's risk of developing disease will become a more realistic outcome. Currently, genetic testing is only helpful for those with known autosomal dominant mutations. This programme is likely to result in several new variants of moderate to strong effect, which may also be used to predict disease in others. The timeline for this impact would be within the next 5 years.
Current animal and cellular models of AD have major limitations. This programme aims to identify genetic variants that have moderate to strong individual effects on disease development. Not only will these provide better animal models than the common risk variants identified so far, but will allow multiple genes to influence models, which may better reflect essential disease components. Currently, most mouse models based upon known disease mutations do not recapitulate the full range of disease symptoms. As we discover more genuine disease causing/risk variants, our ability to produce more realistic disease models will improve. This is likely to have significant impact on the success of commercial testing of new drugs by providing more accurate models. Mouse models could be available within a year of discovery and will be facilitated by our current funded collaborations- Neuromouse funded by the MRC.
In addition, iPSC models that reflect specific genetic risk profiles will be available to the research and commercial communities, directly from this research. This will provide relevant human cellular models to facilitate translation and be available during the course of the grant.
We also aim to identify genes that affect symptoms/characteristics of AD, such as psychosis, depression and rate of decline, which again can be used to target specific disease mechanisms through drug therapy. Similarly, we will test for common disease variants across diseases such as ALS, PD, cardiovascular disease and diabetes. These findings may be used to support drug development for the prevention of or treatment for individuals with or at risk of developing a broad range of diseases. Timelines of 10-15 years, as described above.
Organisations
- Cardiff University (Collaboration, Lead Research Organisation)
- Quest Diagnostics (Collaboration)
- Neuroscience; IOP (Collaboration)
- Eisai Ltd (Collaboration)
- JPND Research (Collaboration)
- Autonomous University of Madrid (Collaboration)
- Jackson Laboratory (Collaboration)
- Boston University (Collaboration)
- Arizona Association for Play Therapy (Collaboration)
- Hospital de Sant Pau (Collaboration)
- University of Pennsylvania (Collaboration)
- Genetic and Environmental Risk in Alzheimer's Disease (GERAD) (Collaboration)
- Ludwig Maximilian University of Munich (LMU Munich) (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- UNIVERSITY OF SOUTHAMPTON (Collaboration)
- University of Bristol (Collaboration)
- University of Manchester (Collaboration)
- University College London (Collaboration)
- UNIVERSITY OF NOTTINGHAM (Collaboration)
- University of Navarra (Collaboration)
- VU University Medical Center (Collaboration)
- National Institute of Health and Medical Research (INSERM) (Collaboration)
- Department of Health Social Services and Public Safety (DHSSPS) (Collaboration)
- Newcastle University (Collaboration)
- Fondazione Santa Lucia (Collaboration)
- Erasmus MC (Collaboration)
- University of Oviedo (Collaboration)
- QUEEN'S UNIVERSITY BELFAST (Collaboration)
- UNIVERSITY OF CAMBRIDGE (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- UNIVERSITY OF EXETER (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- Severnside Alliance for Translational Research (SARTRE) (Collaboration)
- Genetic Architecture of Rate of Alzheimer’s Decline (GENAROAD) Consortium (Collaboration)
- Pasteur Institute, Lille (Collaboration)
- BANGOR UNIVERSITY (Collaboration)
- Eli Lilly & Company Ltd (Collaboration)
- Brigham Young University (Collaboration)
- University of Lille (Collaboration)
- University of Cantabria (Collaboration)
- SWANSEA UNIVERSITY (Collaboration)
- Saarland University (Collaboration)
- Genomics England (Collaboration)
- Guangdong Medical College (Collaboration)
- University of Bonn (Collaboration)
- University of Washington (Collaboration)
- KING'S COLLEGE LONDON (Collaboration)
Publications
Cruchaga C
(2013)
GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease.
in Neuron
Lambert JC
(2013)
Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease.
in Molecular psychiatry
Lambert JC
(2013)
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.
in Nature genetics
Guerreiro R
(2013)
TREM2 variants in Alzheimer's disease.
in The New England journal of medicine
Jones EL
(2013)
Evidence that PICALM affects age at onset of Alzheimer's dementia in Down syndrome.
in Neurobiology of aging
Chapuis J
(2013)
Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology.
in Molecular psychiatry
Landerl K
(2013)
Predictors of developmental dyslexia in European orthographies with varying complexity.
in Journal of child psychology and psychiatry, and allied disciplines
Chapman J
(2013)
A genome-wide study shows a limited contribution of rare copy number variants to Alzheimer's disease risk.
in Human molecular genetics
| Description | Academy Medical Sciences Council Member |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Description | Academy Medical Sciences Fellow |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Membership of a guideline committee |
| Description | Academy Medical Sciences Wales Ambassador |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Description | Associate Director, UK Dementia Research Institute (UKDRI) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Membership of a guideline committee |
| Description | COVID advisory group |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Description | Chief Scientific Advisor, Welsh Government |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Membership of a guideline committee |
| Description | Deputy Director DPUK |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Membership of a guideline committee |
| Description | EPAD LCS sample access committe |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Membership of a guideline committee |
| Description | Medicines Discovery Institute MDI |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Description | NMHRI management |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Description | A high content analysis platform for analysing dementia-associated genetic variation |
| Amount | £108,300 (GBP) |
| Funding ID | ARUK-EG2017A-1 |
| Organisation | Alzheimer's Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 09/2017 |
| Description | ABBUK Brains for Dementia Research Programme (extension) |
| Amount | £404,390 (GBP) |
| Funding ID | 504291 |
| Organisation | Alzheimer’s Brain Bank UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2013 |
| End | 03/2018 |
| Description | Centre for Ageing and Dementia Research (CADR) |
| Amount | £1,200,000 (GBP) |
| Funding ID | 507827 |
| Organisation | Welsh Assembly |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2015 |
| End | 03/2018 |
| Description | Centre for Ageing and Dementia Research (CADR) |
| Amount | £386,341 (GBP) |
| Organisation | Welsh Assembly |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2018 |
| End | 03/2020 |
| Description | Centre for Ageing and Dementia Research - 2 Year Extension |
| Amount | £1,200,000 (GBP) |
| Funding ID | 514840 |
| Organisation | Government of Wales |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2018 |
| End | 03/2020 |
| Description | Defining genetic, polygenic and environmental risk for Alzheimer's disease using multiply powerful cohorts, focussed epigenetics and stem cells |
| Amount | £810,998 (GBP) |
| Funding ID | MR/L501517/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2014 |
| End | 12/2017 |
| Description | Expanding DPUK genetics and integrating with inflammation/immunity research |
| Amount | £100,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 03/2019 |
| Description | IDEA - Integrated DEmentiA research enviornment |
| Amount | £1,882,982 (GBP) |
| Funding ID | MR/M009076/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2015 |
| End | 03/2016 |
| Description | Imaging immunity in the genetic risk for Alzheimer's disease |
| Amount | £191,580 (GBP) |
| Organisation | Government of Wales |
| Department | Welsh European Funding Office |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 09/2021 |
| Description | In vivo imaging of Tau distribution in the brain |
| Amount | £44,743 (GBP) |
| Organisation | Welsh Local Government Association |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2016 |
| End | 03/2017 |
| Description | Investigating PLCG2 and P522R variant PLCG2 in human IPSC models of dementia |
| Amount | £275,000 (GBP) |
| Organisation | Eisai Ltd |
| Department | Eisai Inc |
| Sector | Private |
| Country | United States |
| Start | 06/2018 |
| End | 05/2020 |
| Description | Moondance Centre for Early Onset Alzheimer's Disease |
| Amount | £500,000 (GBP) |
| Organisation | The Moondance Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2015 |
| End | 07/2020 |
| Description | PERADES: Defining genetic, polygenic and environmental risk of Alzheimer's disease using multiple power cohorts, focussed epigentics and stem cell metabolomics |
| Amount | £389,000 (GBP) |
| Funding ID | ARUK-PG2014-1 |
| Organisation | Alzheimer's Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2013 |
| End | 11/2016 |
| Description | The development and implementation of polygenic risk algorithms for stratifying individuals for future cognitive decline due to Alzheimer's disease in non-symptomatic and early cognitive impaired subjects |
| Amount | £293,296 (GBP) |
| Funding ID | 104210 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 02/2020 |
| Description | The development and implementation of polygenic risk algorithms for stratifying individuals for future cognitive decline due to Alzheimers disease |
| Amount | £298,040 (GBP) |
| Funding ID | 2018/20180222 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 03/2020 |
| Description | Therapeutic targeting of impaired lysosomal flux in Alzheimer's disease |
| Amount | £136,502 (GBP) |
| Funding ID | MR/P007651/1 |
| Organisation | Network of Centres of Excellence in Neurodegeneration (COEN) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2016 |
| End | 10/2017 |
| Description | Therapeutic targeting of impaired lysosomal flux in Alzheimer's disease |
| Amount | £136,502 (GBP) |
| Funding ID | MR/P007651/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2016 |
| End | 07/2018 |
| Title | AD Genetics Scotland |
| Description | Blood samples are collected from participants and sent directly from research sites to European Collection of Authenticated Cell Cultures (ECACC), a Culture Collection of Public Health England. Upon arrival, ECACC process the blood and transform into cell lines- peripheral blood lymphocytes (PBLs) and Lymphoblastoid cell lines (LCLs). Cell lines are frozen and stored at ECACC until they are required by the team at Cardiff. |
| Type Of Material | Biological samples |
| Year Produced | 2018 |
| Provided To Others? | No |
| Impact | Ongoing collection of samples, no publications to date. |
| Title | BAC cell lines |
| Description | Bacterial method to insert gene mutations of interest into cell lines |
| Type Of Material | Cell line |
| Provided To Others? | No |
| Impact | none yet |
| Title | CRISPR generated cell lines |
| Description | Cell lines created using genome editing tool |
| Type Of Material | Cell line |
| Provided To Others? | No |
| Impact | none yet |
| Title | EOAD cohort |
| Description | We are collecting a biological sample of early onset Alzheimer's disease individuals for research. This includes phenotypic data and biological data and is set to become the largest EOAD biobank in the world. |
| Type Of Material | Biological samples |
| Provided To Others? | No |
| Impact | This earlier more aggressive form of the disease will be studied in order to shed light on disease mechanisms and prospective therapies. |
| Title | Human Stem Cell Modelling of Brain Disease |
| Description | Cellular models in vitro |
| Type Of Material | Model of mechanisms or symptoms - in vitro |
| Provided To Others? | No |
| Impact | unknown |
| Title | Polygenic score |
| Description | With 80,000 variants included to create a measure of risk of Alzheimer's disease, the polygenic score is an excellent predictive tool to determine case/control status with high accuracy. The polygenic score encompasses the majority of genetic risk of disease, and can be fine-tuned to identify the pathways involved in disease, for example, immune cell activity or endocytosis. |
| Type Of Material | Model of mechanisms or symptoms - human |
| Year Produced | 2016 |
| Provided To Others? | Yes |
| Impact | We are working to translate this method from the basic science environment in which it was created into a predictive tool used to select participants for clinical trials, based on their disease status and type. We are currently in discussions with a number of potential collaborators to take this forward. |
| Title | DPUK Genomics portal |
| Description | The DPUK Genetics portal provides a collaborative platform for individuals, DPUK cohorts and the wider research community to share and access research outputs from genetic research. The platform provides two key tools for finding, sharing and analysing genetic data; The Results Registry tool, accessible via the main DPUK web portal, allows searching and uploading of genetic results data. This tool provides a rich set of search tools specific to genetic data and includes visualisation using the popular JBrowse genomic browser. This tool will allow users to share this data. This can be done under secure data transfer agreements if necessary. The second tool is the Genetic Data Browser this is available exclusively within the secure DPUK infrastructure. This will allow users to create cross-cohort comparison studies based on genotypic datasets and linked phenotypic data. This tool provides an interactive dashboard which can pull in phenotypic data and genetic markers from GWAS data and allow users to intuitively explore, combine and export patient cohorts. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | The DPUK Genetics portal, housed on the DPUK platform, allows non bioinformatic-expert users to explore components of genetic data within a secure environment. We have provided access to an international consortium, GERAD, via the DPUK data portal. This is a dataset of over 18,000 cases and controls (detailed in Table 2), as well as over 5,600 samples to date submitted to the EADB, the European AD DNA bank for deciphering the missing heritability of Alzheimer's disease |
| URL | https://portal.dementiasplatform.uk/ |
| Title | GERAD Exome chip data |
| Description | Dataset from Illumina Exome chip platform (version 1.0 and v1.1), approximately 6,000 cases and 4,000 controls |
| Type Of Material | Database/Collection of data |
| Year Produced | 2014 |
| Provided To Others? | Yes |
| Impact | papers in press |
| Title | IGAP dataset |
| Description | Mega-meta analysis data of over 17,000 AD cases and 30,000 controls |
| Type Of Material | Database/Collection of data |
| Year Produced | 2013 |
| Provided To Others? | Yes |
| Impact | Lambert et al. 2013 (PMID:24162737), Escott-Price et al. 2014(in press), Farrer et al. 2014 (submitted) |
| Description | AD Genetics Cohort, China |
| Organisation | Guangdong Medical College |
| Department | Institute of Neurology |
| Country | China |
| Sector | Public |
| PI Contribution | China remains an untapped unprecedented resource of older individuals for genetic studies. We are working with our contacts there to encourage interest in Alzheimer's disease Genetics. We are using our expertise in cohort genetics including GWAS, whole exome sequences and genome sequencing to gather up the most powerful cohort possible for the identification of Alzheimer's changes. So far we have brought PIs from six Chinese Universities on board. We have discussed the issues surrounding governance and compliance for the particular materials needed for the study. We have decided on a functional study plan together and hope to develop this for future funding in order to make use of this readily available resource, |
| Collaborator Contribution | Each of the Chinese Institutions approached have agreed to enter into an agreement with Cardiff. This will allow the production of genetic data from a variety of Alzheimer's and Control genetic samples. These data will be fully analysed and compared to that from other populations. The project current status is awaiting the necessary legal agreements required before information can be shared between Institutions. |
| Impact | This collaboration includes individuals with expertise in compliance, legal, sample collection, cohort genetics, bioinformatics, statistics, data interpretaton. It is not anticipated that additional resources will be available to investigate other dementia types or neurological conditions. |
| Start Year | 2015 |
| Description | ADES Collaboration |
| Organisation | Erasmus MC |
| Country | Netherlands |
| Sector | Hospitals |
| PI Contribution | A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this. |
| Collaborator Contribution | as above |
| Impact | n/a |
| Start Year | 2016 |
| Description | ADES Collaboration |
| Organisation | Hospital de Sant Pau |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this. |
| Collaborator Contribution | as above |
| Impact | n/a |
| Start Year | 2016 |
| Description | ADES Collaboration |
| Organisation | National Institute of Health and Medical Research (INSERM) |
| Country | France |
| Sector | Academic/University |
| PI Contribution | A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this. |
| Collaborator Contribution | as above |
| Impact | n/a |
| Start Year | 2016 |
| Description | ADES Collaboration |
| Organisation | Pasteur Institute, Lille |
| Country | France |
| Sector | Charity/Non Profit |
| PI Contribution | A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this. |
| Collaborator Contribution | as above |
| Impact | n/a |
| Start Year | 2016 |
| Description | ADES Collaboration |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this. |
| Collaborator Contribution | as above |
| Impact | n/a |
| Start Year | 2016 |
| Description | ADES Collaboration |
| Organisation | University of Bonn |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this. |
| Collaborator Contribution | as above |
| Impact | n/a |
| Start Year | 2016 |
| Description | ADES Collaboration |
| Organisation | University of Pennsylvania |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this. |
| Collaborator Contribution | as above |
| Impact | n/a |
| Start Year | 2016 |
| Description | ADES Collaboration |
| Organisation | VU University Medical Center |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this. |
| Collaborator Contribution | as above |
| Impact | n/a |
| Start Year | 2016 |
| Description | AZAPT |
| Organisation | Arizona Association for Play Therapy |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | MOLECULAR BIOLOGY, data analysis, cell culture |
| Collaborator Contribution | MOLECULAR BIOLOGY, data analysis, cell culture |
| Impact | none yet |
| Start Year | 2014 |
| Description | Brains for Dementia Research |
| Organisation | King's College London |
| Department | Clinical Neuroscience |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Overall Management of BDR Centre, recruitment and Brain Banking |
| Collaborator Contribution | Overall Management of BDR Centre, recruitment and Brain Banking |
| Impact | BDR aims to set a gold standard for brain donation by coordinating brain banks across the country and providing high quality tissue to researchers. We hope to enable more people to get involved in brain donation, thus boosting the number of brains available for this important research. BDR is unique because every brain donor is monitored throughout their later life. This means that a complete medical history is available to accompany their donated brain tissue. This is crucial to allow researchers to make the most of donated tissue. BDR run an online database of brain tissue. Researchers can search the database and apply to BDR for samples. |
| Start Year | 2013 |
| Description | Brains for Dementia Research |
| Organisation | Newcastle University |
| Department | Institute for Ageing and Health |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Overall Management of BDR Centre, recruitment and Brain Banking |
| Collaborator Contribution | Overall Management of BDR Centre, recruitment and Brain Banking |
| Impact | BDR aims to set a gold standard for brain donation by coordinating brain banks across the country and providing high quality tissue to researchers. We hope to enable more people to get involved in brain donation, thus boosting the number of brains available for this important research. BDR is unique because every brain donor is monitored throughout their later life. This means that a complete medical history is available to accompany their donated brain tissue. This is crucial to allow researchers to make the most of donated tissue. BDR run an online database of brain tissue. Researchers can search the database and apply to BDR for samples. |
| Start Year | 2013 |
| Description | Brains for Dementia Research |
| Organisation | University of Bristol |
| Department | Dementia Research Group |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Overall Management of BDR Centre, recruitment and Brain Banking |
| Collaborator Contribution | Overall Management of BDR Centre, recruitment and Brain Banking |
| Impact | BDR aims to set a gold standard for brain donation by coordinating brain banks across the country and providing high quality tissue to researchers. We hope to enable more people to get involved in brain donation, thus boosting the number of brains available for this important research. BDR is unique because every brain donor is monitored throughout their later life. This means that a complete medical history is available to accompany their donated brain tissue. This is crucial to allow researchers to make the most of donated tissue. BDR run an online database of brain tissue. Researchers can search the database and apply to BDR for samples. |
| Start Year | 2013 |
| Description | Brains for Dementia Research |
| Organisation | University of Manchester |
| Department | Institute of Brain, Behaviour and Mental Health |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Overall Management of BDR Centre, recruitment and Brain Banking |
| Collaborator Contribution | Overall Management of BDR Centre, recruitment and Brain Banking |
| Impact | BDR aims to set a gold standard for brain donation by coordinating brain banks across the country and providing high quality tissue to researchers. We hope to enable more people to get involved in brain donation, thus boosting the number of brains available for this important research. BDR is unique because every brain donor is monitored throughout their later life. This means that a complete medical history is available to accompany their donated brain tissue. This is crucial to allow researchers to make the most of donated tissue. BDR run an online database of brain tissue. Researchers can search the database and apply to BDR for samples. |
| Start Year | 2013 |
| Description | Brains for Dementia Research |
| Organisation | University of Oxford |
| Department | Oxford Parkinson's Disease Centre (OPDC) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Overall Management of BDR Centre, recruitment and Brain Banking |
| Collaborator Contribution | Overall Management of BDR Centre, recruitment and Brain Banking |
| Impact | BDR aims to set a gold standard for brain donation by coordinating brain banks across the country and providing high quality tissue to researchers. We hope to enable more people to get involved in brain donation, thus boosting the number of brains available for this important research. BDR is unique because every brain donor is monitored throughout their later life. This means that a complete medical history is available to accompany their donated brain tissue. This is crucial to allow researchers to make the most of donated tissue. BDR run an online database of brain tissue. Researchers can search the database and apply to BDR for samples. |
| Start Year | 2013 |
| Description | CADR |
| Organisation | Bangor University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | sample preparation, data analysis |
| Collaborator Contribution | data analysis, sample collections |
| Impact | none yet |
| Start Year | 2014 |
| Description | CADR |
| Organisation | Swansea University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | sample preparation, data analysis |
| Collaborator Contribution | data analysis, sample collections |
| Impact | none yet |
| Start Year | 2014 |
| Description | CFAS |
| Organisation | Bangor University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We are working together with CFAS to prepare the 3,000 participant cohort for genetic research. |
| Collaborator Contribution | Provided cohort |
| Impact | CFAS prepared for Genetic analysis |
| Start Year | 2009 |
| Description | CFAS |
| Organisation | Swansea University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We are working together with CFAS to prepare the 3,000 participant cohort for genetic research. |
| Collaborator Contribution | Provided cohort |
| Impact | CFAS prepared for Genetic analysis |
| Start Year | 2009 |
| Description | Caerphilly Cohort |
| Organisation | Cardiff University |
| Department | School of Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | AD expertise, Genotyping, Data analysis, study design |
| Collaborator Contribution | DNA, Epidemiological data, data analysis, study design |
| Impact | unknown |
| Start Year | 2012 |
| Description | Caerphilly Cohort |
| Organisation | University of Bristol |
| Department | Avon Longitudinal Study of Parents and Children (ALSPAC) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | AD expertise, Genotyping, Data analysis, study design |
| Collaborator Contribution | DNA, Epidemiological data, data analysis, study design |
| Impact | unknown |
| Start Year | 2012 |
| Description | Caerphilly Cohort |
| Organisation | University of Cambridge |
| Department | MRC Cognitive Function and Ageing Study (CFAS) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | AD expertise, Genotyping, Data analysis, study design |
| Collaborator Contribution | DNA, Epidemiological data, data analysis, study design |
| Impact | unknown |
| Start Year | 2012 |
| Description | Dementia Platform UK (DPUK) |
| Organisation | Department of Health Social Services and Public Safety (DHSSPS) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Biostatistical analysis and epidemiological |
| Collaborator Contribution | sample collections / cohorts, data and molecular biology |
| Impact | none yet |
| Start Year | 2014 |
| Description | EPAD |
| Organisation | GlaxoSmithKline (GSK) |
| Department | Epidemiology |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | GENOTYPING AND ANALYSIS |
| Collaborator Contribution | cohorts, biomarker studies, epidemiological studies, random control studies |
| Impact | none yet |
| Start Year | 2014 |
| Description | Eisai Collaboration |
| Organisation | Eisai Ltd |
| Country | Japan |
| Sector | Private |
| PI Contribution | We are identifying important genes and pathways involved in Alzheimer's disease for further investigation in functional experiments and drug-based tests. |
| Collaborator Contribution | Expertise in functional biology |
| Impact | None yet |
| Start Year | 2015 |
| Description | Eli Lilly Collaboration |
| Organisation | Cardiff University |
| Department | School of Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Access to patient bio-samples, co-directs study design |
| Collaborator Contribution | scientific input, co-direct study design, funding |
| Impact | unknown |
| Start Year | 2012 |
| Description | Eli Lilly Collaboration |
| Organisation | Eli Lilly & Company Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Access to patient bio-samples, co-directs study design |
| Collaborator Contribution | scientific input, co-direct study design, funding |
| Impact | unknown |
| Start Year | 2012 |
| Description | Finding genes for late onset Alzheimer's disease: Collaboration between Washington University, NIMH, Cardiff University and Celera Diagnostics |
| Organisation | Quest Diagnostics |
| Department | Celera Diagnostics |
| Country | United States |
| Sector | Private |
| PI Contribution | We undertook a genomewide association study of Alzheimer's disease using genetic pooling and also tested associations with candidate genes. The Celera Diagnostics through a sub-contract with MERCK paid for the genomewide association genotyping. Our group took the lead on some studies and contributed samples and intellectual input on others but at all stages all decisions about research design etc were undertaken jointly in a full collaborative fashion. This built on a previous collaboration between ourselves and Allison Goates group from Washington University which spanned over a decade. |
| Collaborator Contribution | Our collaborative group including Celera Diagnostics, Allison Goate and John Hardys research groups undertook a genomewide association study of Alzheimer's disease using genetic pooling and also tested associations with candidate genes. Celera Diagnostics through a sub-contract with MERCK paid for the genomewide association genotyping. Our group took the lead on some studies and contributed samples and intellectual input on others but at all stages all decisions about research design etc were undertaken jointly in a full collaborative fashion. This built on a previous collaboration between ourselves and Allison Goates group from Washington University which spanned over a decade. |
| Impact | 17949987 17492769 17725986 18063669 16161859 16385451 16278862 16847012 17317784 |
| Description | GENAROAD |
| Organisation | Genetic Architecture of Rate of Alzheimer’s Decline (GENAROAD) Consortium |
| Country | Global |
| Sector | Charity/Non Profit |
| PI Contribution | data and analyses |
| Collaborator Contribution | data analysis |
| Impact | none yet, paper being prepared for publication |
| Start Year | 2013 |
| Description | GERAD Exome Chip Consortium |
| Organisation | Autonomous University of Madrid |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | Brigham Young University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | Cardiff University |
| Department | School of Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | Fondazione Santa Lucia |
| Country | Italy |
| Sector | Charity/Non Profit |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | Hospital de Sant Pau |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | Ludwig Maximilian University of Munich (LMU Munich) |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | Neuroscience; IOP |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | Queen's University Belfast |
| Department | Aging group |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | Saarland University |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | University College London |
| Department | MRC Prion Unit |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | University of Bonn |
| Department | Department of Psychiatry |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | University of Cantabria |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | University of Navarra |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | University of Nottingham |
| Department | Centre for Genetics and Genomics |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | University of Oviedo |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | University of Southampton |
| Department | Clinical and Experimental Sciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | University of Washington |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | Genomics England |
| Organisation | Genomics England |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | We are in the very early stages of discussion with Genomics England, but we hope to be able to use their facilities for whole Genome sequencing. This will mean that we generate valuable data on the largest EOAD cohort world-wide. |
| Collaborator Contribution | Genomics England have the equipment and infrastructure set up for the very expensive and technical whole exome sequencing. |
| Impact | None yet |
| Start Year | 2015 |
| Description | GlaxoSmithKline Cardiff Collaboration |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | Prof Williams made contact with a GSK rep at the Global Genetics Congress in Baltimore, September 2016. GSK were extremely interested in collaborating with the Cardiff team. Specifically, GSK have an interest in the latest confidential experimental results and translating these from genetic to biological meaning. This will speed up the Cardiff Team's discovery of potential molecular targets for personalised disease treatment. Cardiff will contribute expertise in Alzheimer's disease genetics. |
| Collaborator Contribution | GSK will contribute their expertise in disease models and drug mechanisms. |
| Impact | This collaboration has been brought under a confidentiality agreement. Parties involved are experts in genetics and functional biology. |
| Start Year | 2016 |
| Description | International Genomics of Alzheimer's Project (IGAP) |
| Organisation | Boston University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Co-leadership, management, DNA from AD cases and controls, GWAS data from AD cases and controls, data analysis and joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation, data analysis |
| Impact | papers in progress |
| Start Year | 2012 |
| Description | International Genomics of Alzheimer's Project (IGAP) |
| Organisation | Genetic and Environmental Risk in Alzheimer's Disease (GERAD) |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Co-leadership, management, DNA from AD cases and controls, GWAS data from AD cases and controls, data analysis and joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation, data analysis |
| Impact | papers in progress |
| Start Year | 2012 |
| Description | International Genomics of Alzheimer's Project (IGAP) |
| Organisation | University of Lille |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Co-leadership, management, DNA from AD cases and controls, GWAS data from AD cases and controls, data analysis and joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation, data analysis |
| Impact | papers in progress |
| Start Year | 2012 |
| Description | International Genomics of Alzheimer's Project (IGAP) |
| Organisation | University of Pennsylvania |
| Department | Alzheimer's Disease Genetics Consortium (ADGC) |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Co-leadership, management, DNA from AD cases and controls, GWAS data from AD cases and controls, data analysis and joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation, data analysis |
| Impact | papers in progress |
| Start Year | 2012 |
| Description | JPND PERADES |
| Organisation | JPND Research |
| Country | Global |
| Sector | Academic/University |
| PI Contribution | Coordinator of the EU Joint Programme - Neurodegenerative Disease Research PERADES project |
| Collaborator Contribution | Containing researchers from 11 countries. Exploiting new statistical approaches to genetic data, researchers will calculate polygenic risk scores and use these to identify individuals at both high and low risk of developing Alzheimer's disease. |
| Impact | The JPND project brings together researchers across Europe to perform vast replication studies of variants of interest in Alzheimer's disease. The project is also the first to begin exome sequencing of the EOAD cohort, which we hope will shed light on the early stages of disease. Importantly, this project brings together the areas of genetics, a variety of omics, polygenic scores, and population studies in a powerful combination to further our knowledge of Alzheimer's disease. |
| Start Year | 2013 |
| Description | Jackson labs collaboration |
| Organisation | The Jackson Laboratory |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | We provide the most up to date genetic human Alzheimer's disease study results and interpretation. |
| Collaborator Contribution | Jackson labs provide their expertise in translation of human study findings into small animal transgenic models of genetic diseases. |
| Impact | Attempts so far to tie down both a project plan and committed funding, have not been successful. We are currently exploring alternative methods to whole animal experiments. We hope that in the future we will be able to regenerate interest in this promising collaboration. |
| Start Year | 2016 |
| Description | PROTECT / CHARIOT-Pro / Cardiff DPUK |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Genotyping of 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be completed by Cardiff Univ as part of a collaboration funded by Dementias Platform UK. Polygenic risk scores will be calculated for these individuals and data made available via DPUK Platform. |
| Collaborator Contribution | DNA samples from 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be sent to Cardiff Univ for genotyping |
| Impact | None to date - work in progress. Collaboration is multi-disciplinary - Neurology, Neuroepidemiology & Ageing; Genetics & Genomics; Psychiatry |
| Start Year | 2018 |
| Description | PROTECT / CHARIOT-Pro / Cardiff DPUK |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Genotyping of 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be completed by Cardiff Univ as part of a collaboration funded by Dementias Platform UK. Polygenic risk scores will be calculated for these individuals and data made available via DPUK Platform. |
| Collaborator Contribution | DNA samples from 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be sent to Cardiff Univ for genotyping |
| Impact | None to date - work in progress. Collaboration is multi-disciplinary - Neurology, Neuroepidemiology & Ageing; Genetics & Genomics; Psychiatry |
| Start Year | 2018 |
| Description | PROTECT / CHARIOT-Pro / Cardiff DPUK |
| Organisation | University of Exeter |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Genotyping of 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be completed by Cardiff Univ as part of a collaboration funded by Dementias Platform UK. Polygenic risk scores will be calculated for these individuals and data made available via DPUK Platform. |
| Collaborator Contribution | DNA samples from 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be sent to Cardiff Univ for genotyping |
| Impact | None to date - work in progress. Collaboration is multi-disciplinary - Neurology, Neuroepidemiology & Ageing; Genetics & Genomics; Psychiatry |
| Start Year | 2018 |
| Description | Translating the effects of new susceptibility genes for AD into disease mechanisms and potential drug screening |
| Organisation | Cardiff University |
| Department | School of Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | AD expertise, genotying, data analysis, study design, co-supervision of research fellow Amy Gerrish |
| Collaborator Contribution | Functional expertise, study design, co-supervision of research fellow Amy Gerrish |
| Impact | unknown |
| Start Year | 2012 |
| Description | Translating the effects of new susceptibility genes for AD into disease mechanisms and potential drug screening |
| Organisation | Severnside Alliance for Translational Research (SARTRE) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | AD expertise, genotying, data analysis, study design, co-supervision of research fellow Amy Gerrish |
| Collaborator Contribution | Functional expertise, study design, co-supervision of research fellow Amy Gerrish |
| Impact | unknown |
| Start Year | 2012 |
| Description | Using worms and flies to screen human genes associated with Alzheimer's disease |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | AD expertise, GWAS data |
| Collaborator Contribution | Functional expertise, Model organisms |
| Impact | unknown |
| Start Year | 2008 |
| Description | Using worms and flies to screen human genes associated with Alzheimer's disease |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | AD expertise, GWAS data |
| Collaborator Contribution | Functional expertise, Model organisms |
| Impact | unknown |
| Start Year | 2008 |
| Description | 11 new susceptibility genes linked with Alzheimer's disease |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | In the largest ever study of its kind, an international collaboration of scientists, jointly led by Cardiff, has uncovered 11 new susceptibility genes linked with Alzheimer's disease. Worldwide TV and Newspaper Coverage received |
| Year(s) Of Engagement Activity | 2013 |
| Description | 2 new genetic variations linked with Alzheimer's |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | An international collaboration of scientists, including expertise from Cardiff University, has uncovered two new genetic variations linked with Alzheimer's, opening up new research avenues into the disease. The two newly discovered genetic variations do not predict a person's risk of developing Alzheimer's, but the authors of the paper, which appears in The Journal of the American Medical Association (JAMA) speak of new valuable insights for scientists working on the disease. Professor Julie Williams, Cardiff University, is a principal investigator of the study, led by Professor Monique Breteler, University Medical Center Rotterdam. The research also builds on the discovery led by Professor Williams last year of the first new genes associated with Alzheimer's in a generation. Unknown |
| Year(s) Of Engagement Activity | 2010 |
| Description | 2013 Open Day |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | Yes |
| Geographic Reach | Regional |
| Primary Audience | Undergraduate students |
| Results and Impact | 150 people attended an open day which included a series of talks, poster presentations, lab tours and informal question and answer sessions. The event was featured on the BBC Radio Wales Science Cafe Show which resulted in increased enquiries from members of the public. |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://www.alzheimersresearchuk.org/news-detail/10941/Public-invited-to-day-of-dementia-talks-tours-... |
| Description | 5 new Alzheimer's genes |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | A leading University scientist's search for factors that increase the risk of developing Alzheimer's has uncovered five new genes to help pinpoint what's going wrong in the brain. Professor Julie Williams from the University's MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, has identified an additional five new genes - bringing the total number of genes that increase the risk of developing Alzheimer's to ten. (BBC Radio 4, Today programme, BBC Radio Wales, Good Morning Wales, BBC Wales Breakfast News, ITV Wales Breakfast News; BBC On-line, 4.4.2011, www.bbc.co.uk/news/health-12937131; The Mirror, 4.4.11, www.mirror.co.uk/news/top-stories/2011/04/04/genetic-study-uncovers-causes-of-alzheimer-s-disease-115875-23036111/; The Independent, 4.4.11, http://www.independent.co.uk/news/science/a-test-for-alzheimers-disease-ndash-but-will-anyone-want-to-take-it-2261426.html; The Telegraph, 4.4.11, www.telegraph.co.uk/health/healthnews/8422477/New-genes-found-in-hunt-for-Alzheimers-disease-cure.html; Daily Mail, 4.4.11, www.dailymail.co.uk/health/article-1373063/The-genetic-clues-help-prevent-Alzheimers-disease.html?ito=feeds-newsxml; Unknown |
| Year(s) Of Engagement Activity | 2011 |
| Description | AAIC Los Angeles Annual Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | MODEL-AD presentation - Alzheimer's Susceptibility Genes Implicate Microglial Activity |
| Year(s) Of Engagement Activity | 2019 |
| Description | AMS fellowship workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | Organisation of a Academy of Medical Science workshop by J Williams as Wales AMS Champion to encourage applications from young researchers to become AMS fellows |
| Year(s) Of Engagement Activity | 2019 |
| Description | ART - Westminster |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Dissemination of research findings to parliamentarians not known |
| Year(s) Of Engagement Activity | 2010 |
| Description | ART Event - Bournemouth |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | Yes |
| Geographic Reach | Regional |
| Primary Audience | Participants in your research and patient groups |
| Results and Impact | Disseminating research findings to research participants not know |
| Year(s) Of Engagement Activity | 2009 |
| Description | ART Public Lecture |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Presented research findings as part of the ART public lecture "New Alzheimer's genes: What do they mean?" Not Known |
| Year(s) Of Engagement Activity | 2010 |
| Description | ARUK 2014 Annual Meeting |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | Yes |
| Type Of Presentation | keynote/invited speaker |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | Julie Williams took part in a debate at the 2014 ARUK conference titled: Alzheimer's disease: The relative importance of Genes and Environment The conference audience took part in the debate and positive feedback was recieved about this part of the conference. |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www.alzheimersresearchuk.org/conference-programme/ |
| Description | ARUK Conference |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Attendee at online conference |
| Year(s) Of Engagement Activity | 2022 |
| Description | ARUK Iceland donation press release |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | A press release was issued announcing new funding from ARUK raised by Iceland foods The press release mentioned research investigating Early Onset AD, this resulted in an increase in enquiries about research |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www.alzheimersresearchuk.org/news-detail/10984/Cardiff-researchers-lead-global-hunt-for-early... |
| Description | ARUK Public Engagement open day |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Public engagement |
| Year(s) Of Engagement Activity | 2015 |
| Description | ARUK Scientific meeting |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other audiences |
| Results and Impact | Scientific meeting |
| Year(s) Of Engagement Activity | 2015 |
| Description | ARUK network 2019 Exeter |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | The event was organised between the ARUK Bristol & Bath, Southwest (Exeter and Plymouth) and Wales networks. The aim was for members to meet, showcase research & build collaborations. J Williams spoke on Research infrastructure and resources: UKDRI as member of Cardiff University and UK Brain Banks Network |
| Year(s) Of Engagement Activity | 2019 |
| Description | Alzheimer's Research UK trustee talk and lab tour |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Presentation for lay members of Alzheimer's Research UK unknown |
| Year(s) Of Engagement Activity | 2012 |
| Description | Alzheimer's Society legacy event |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | Yes |
| Geographic Reach | Regional |
| Primary Audience | Supporters |
| Results and Impact | Dr Rebecca Sims spoke at an Alzheimer's Society legacy event An increase in legacy donations |
| Year(s) Of Engagement Activity | 2013 |
| Description | Alzheimer's gene study achieves landmark breakthrough |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Cardiff University publicised publication in Nature Genetics "Genetic meta-analysis of diagnosed Alzheimer's disease identifies novel risk loci and implicates Abeta, Tau, immunity and lipid processing" - aiming to raise public awareness of research being undertaken at UK Dementia Research Institute Cardiff |
| Year(s) Of Engagement Activity | 2019 |
| Description | Alzheimers Society Visit |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Health professionals |
| Results and Impact | presented research findings to representatives of ART at a visit hosted by the Dean of Medicine, Cardiff University not known |
| Year(s) Of Engagement Activity | 2010 |
| Description | Annual ART Conference |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Participants in your research and patient groups |
| Results and Impact | Attended and presented at the annual ART conference not known |
| Year(s) Of Engagement Activity | 2010 |
| Description | Awarded £800K to lead new genetic research into Alzheimer's |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Professor Julie Williams, School of Medicine, has been awarded £800K to lead new genetic research into Alzheimer's (Business Weekly, 14.10.10) Unknown |
| Year(s) Of Engagement Activity | 2010 |
| Description | BBC (online and local news) |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Prof Julie Williams on AD gene study |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.bbc.co.uk/news/uk-wales-36286847 |
| Description | BBC Panorama |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Prof Julie Williams Research Team were approached to be involved in a BBC documentary. The documentary followed one of our research participants and his family through everyday life with Alzheimer's disease. Field workers and laboratory staff were also filmed in their roles. The documentary was screened on BBC1 in Panorama on 2nd June 2016. |
| Year(s) Of Engagement Activity | 2016 |
| Description | BBC Wales Dementia Week 2016 |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Filming with BBC Wales's Owain Clarke on Thursday (12th May, 10-12). Interview is part of a package he's doing for Alzheimer's Awareness Week. Owain will be asking Prof Williams about Wales's research contribution; her own specific research and; look ahead at what's next. Various excerpts were screened on BBC news throughout the week, featuring a number of different staff from the team at Cardiff. This raised awareness of our work and the profile of the team. |
| Year(s) Of Engagement Activity | 2016 |
| Description | BBC Wales evening news UK DRI Cardiff official opening |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Interview of Professor Julie Williams to publicise official opening of UK DRI Cardiff. Prof Williams explained the purpose of the DRI, its multi-targeted approach, and the funding that had enabled attraction of world class scientists to Cardiff. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.bbc.co.uk/iplayer/episode/b0bp0k0t/bbc-wales-today-evening-news-25102018# |
| Description | BBC panorama |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | BBC Panorama are following an EOAD participant. The initial interview was filmed by the BBC |
| Year(s) Of Engagement Activity | 2016 |
| Description | BBC radio interview |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Radio interview BBC Forty research groups led by scientists in Cardiff, France and the United States have been working more closely together and have now pooled a worldwide database of 90,000 samples. "We're about to submit a paper that is enormously exciting and which I think will really change, without a doubt, what we think of Alzheimer's disease going forward," Professor Julie Williams, head of the research team at Cardiff University, said. "Over the last five or six years we've been successful in identifying 30 genes that increase - or decrease - your risk for Alzheimer's disease. Now this is telling us what some of the major components in disease development are. It's new, it's exciting; it's a different perspective on what Alzheimer's disease is." |
| Year(s) Of Engagement Activity | 2018 |
| URL | http://www.bbc.co.uk/news/uk-wales-36286847 |
| Description | Brain Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | The Guarantors of Brain was set up to promote teaching, education and research in neurology and related disciplines. In 2021, we put on our first conference - run as a 2-day online conference, with a focus on clinical neurology and research. The conference was attended by almost 2000 delegates across the globe. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Brain Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Invited speaker |
| Year(s) Of Engagement Activity | 2022 |
| Description | British Neuroscience Conference, Harrogate |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Finding genes for developmental dyslexia unknown |
| Year(s) Of Engagement Activity | 2011 |
| Description | British Science Festival 2016 Workshops |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | We used VR tools to demonstrate the impact of dementia on people's everyday lives. These included using the experiences "A Walk Through Dementia", our citizen science game "Sea Hero Quest", some activities from out children's website, as well as hands on activities and memory games. |
| Year(s) Of Engagement Activity | 2016 |
| URL | https://www.britishsciencefestival.org/ |
| Description | Building CanadaUK collaborations in neurodegenerative disease |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Seminar at the High Comission of Canada unknown |
| Year(s) Of Engagement Activity | 2012 |
| Description | CADR Annual Public Conference, 5th October 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | The Centre for Aging and Dementia Research (CADR) annual public meeting was held on 5th October in City Hall, Cardiff. A variety of individuals attended including the general public, and NHS staff working in dementia. Feedback received indicated that the event was regarded as training for NHS staff. Discussion groups were lively, and focused on clinical dementia. A number of information stands were manned during the meeting, including an ARUK stand, a Cardiff University Alzheimer's Team Recruitment stand, a Join Dementia Research (JDR) Stand, and a variety of others. The Cardiff research team have had an increased number of volunteer queries. We have also furthered collaborations with CFAS Wales, Dr John Hindle (DLB/PD expert) and others as a direct result of this meeting. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.cadr.cymru/en/ |
| Description | CADR Presentation to Minister |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Policymakers/politicians |
| Results and Impact | The Welsh Assembly Government Minister for Health visited Swansea University on 15th August, 2016. CADR staff/scientific leads were asked to prepare short presentations to inform the Minister of the on-going work of the research teams involved in CADR. Prof Julie Williams gave a brief presentation about the research of her team |
| Year(s) Of Engagement Activity | 2016 |
| Description | CNS Leadership Seminar: The quest to slow Alzheimer's disease progression |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Provided a talk entitled "Genetic basis of Alzheimer disease susceptibility" at the CNS Leadership Seminar: The quest to slow Alzheimer's disease progression Unknown |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://onenucleus.com/onenucleus-events?id=692 |
| Description | CURE ND Workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Workshop to discuss disease models in the field of neurodegeneration, what are the most advanced models to date, how accurate are they, and what is missing in terms of modelling |
| Year(s) Of Engagement Activity | 2021 |
| Description | Calling for more funding for research into dementia |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Professor Julie Williams and Professor Mike Owen, Cardiff University are calling for more funding for research into dementia. (Western Mail, 9/2/11, p5) Unknown |
| Year(s) Of Engagement Activity | 2011 |
| Description | Cardiff Scientific Society |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Talk entitled - The Genetics underlying late-onset Alzheimer's Disease Not Known |
| Year(s) Of Engagement Activity | 2010 |
| Description | Cardiff experts call for Alzheimer's action |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Cardiff experts have been at the forefront of calls to step up the battle against Alzheimer's Disease in the press and on national television following a leading international conference on the disease. Nationwide media coverage including the BBC news Will lead to increased public awareness |
| Year(s) Of Engagement Activity | 2010 |
| Description | Cheltenham Science Festival |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | The Festival theme 2019 was health and wellbeing, considering everything from the food we eat and our exercise regimes to cutting-edge medical research. As part of this theme, the event explored the latest breakthroughs in dementia research. The panel was asked to talk about the broad landscape in this field and its evolution in recent years, key achievements and challenges and an insight into how the diagnosis and treatment of dementia has changed and developed. J Williams talked about cutting-edge research and expertise and the exciting aspects of her own work within this area As populations have aged, dementia has become the fifth biggest cause of death worldwide. Yet despite its devastating consequences there is currently no cure. What do we know about this group of diseases, and are there things we can do to help reduce our risks and keep our brains fighting fit? Alzheimer's disease specialist Julie Williams and psychiatrist Ivan Koychev discuss the latest breakthroughs and discoveries that are helping to prevent, diagnose and treat dementia more effectively. |
| Year(s) Of Engagement Activity | 2011,2019 |
| Description | Defining the genetic architecture of AD |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Health professionals |
| Results and Impact | Rome 28th February 2011 - Invited speaker Unknown |
| Year(s) Of Engagement Activity | 2011 |
| Description | Defining the genetic architecture of Alzheimer's disease |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Presentation for the Waterloo foundation unknown |
| Year(s) Of Engagement Activity | 2012 |
| Description | Defining the genetic architecture of Alzheimer's disease |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Royal College of Psychiatrists International Congress 29th June 2011 - Invited speaker Unknown |
| Year(s) Of Engagement Activity | 2011 |
| Description | Defining the genetic architecture of Alzheimer's disease |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Health professionals |
| Results and Impact | German National Genome Research Network (NGFN) Conference - 27th September 2011 - Keynote speaker Unknown |
| Year(s) Of Engagement Activity | 2011 |
| Description | Defining the genetic architecture of Alzheimer's disease |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Health professionals |
| Results and Impact | College of Mental Health Pharmacy , Leicestershire 30th September 2011 - Keynote speaker Unknown |
| Year(s) Of Engagement Activity | 2011 |
| Description | Defining the genetic architecture of Alzheimer's disease |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Health professionals |
| Results and Impact | Alzheimer's Research Trust Research Day - Manchester ART Centre, Chancellors conference centre 27th January 2011 - Keynote speaker Unknown |
| Year(s) Of Engagement Activity | 2011 |
| Description | Dementia - A National Symposium 2013 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Delivered a talk entitled "Identifying and understanding genes which increase the risk of developing Alzheimer's disease and other dementias" Unknown |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://www.open.ac.uk/science/main/files/science/file/Dementia%202013%20-%20Programme.pdf |
| Description | Dementia research at the Cardiff City stadium |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Professor Julie Williams, School of Medicine, will be among a set of leading speakers discussing dementia research at the Cardiff City stadium today (South Wales Echo, 22.05.11, Pg 10) Unknown |
| Year(s) Of Engagement Activity | 2011 |
| Description | Dementia: Making a Difference. Television Programme for BBC2 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Television programme about the work of Julie Williams http://www.bbc.co.uk/programmes/b01j0qwr unknown |
| Year(s) Of Engagement Activity | 2012 |
| Description | Distribution of news letter |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | Yes |
| Geographic Reach | Regional |
| Primary Audience | Participants in your research and patient groups |
| Results and Impact | We distribute a 4-8 page newsletter annually to participants in our research, their families and healthcare professionals At present just over 1000 people receive our newsletter. The newsletter helps engage the public in our research and we receive a large amount of positive feedback from it. We also hope that the newsletter has a positive impact on retention of participants in longitudinal aspects of our research. |
| Year(s) Of Engagement Activity | 2006,2007,2008,2009,2010,2011,2012,2013,2014 |
| Description | EISA Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Health professionals |
| Results and Impact | Delivered talk entitled - Dementia and Cognitive Dysfunction Unknown |
| Year(s) Of Engagement Activity | 2010 |
| Description | Eli Lilly Seminar |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Defining the genetic architecture of Alzheimer's Disease unknown |
| Year(s) Of Engagement Activity | 2011 |
| Description | Finding genes for developmental dyslexia |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Health professionals |
| Results and Impact | 7th International Conference - British Dyslexia Association 2 - 5th June 2011 - Invited speaker Unknown |
| Year(s) Of Engagement Activity | 2011 |
| Description | Finding the causes of Alzheimer's disease |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Delivered a public lecture as part of the Science in Health Public Lecture Series entitled "Finding the causes of Alzheimer's disease" Unknown |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://medicine.cf.ac.uk/event/finding-the-causes-of-alzheimers-disease/ |
| Description | Fiona Phillips visit |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Journalist and broadcaster Fiona Phillips is to visit the University's MRC Centre for Neuropsychiatric Genetics and Genomics this week to investigate leading Alzheimer's research. (South Wales Echo, 21.07.11, p.9) Unknown |
| Year(s) Of Engagement Activity | 2011 |
| Description | Funding for Alzheimer's research |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Professor Julie Williams, School of Medicine, is interviewed regarding funding for Alzheimer's research. (BBC Radio Wales, 2.2.10) Unknown |
| Year(s) Of Engagement Activity | 2010 |
| Description | Funding for Alzheimer's research |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Scientists in Wales researching the causes of dementia are at a "major disadvantage" because the nation does not fund such projects says Professor Julie Williams, School of Medicine. (Western Mail, 4/2/10, p14) Professor Williams is also interviewed about funding for Alzheimer's research. (BBC Wales News, 4/2/10) Unknown |
| Year(s) Of Engagement Activity | 2009 |
| Description | Funding for medical research is dangerously low |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Professor Julie Williams, School of Medicine, says funding for medical research is dangerously low. (Daily Telegraph 9.2.11 http://www.medicalnewstoday.com/articles/216363.php ) Unknown |
| Year(s) Of Engagement Activity | 2011 |
| Description | Further insights into the causes of Alzheimer's disease |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | UN Older Persons' Day - 29th Sept 2011 - Invited speaker Unknown |
| Year(s) Of Engagement Activity | 2011 |
| Description | GEHC/CU Symposium |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | Local |
| Primary Audience | Third sector organisations |
| Results and Impact | Provided a talk entitled "Opportunities in Wales: WG" at the Joint GE Healthcare / Cardiff University Symposium (Theme: Stem Cell technologies) Unknown |
| Year(s) Of Engagement Activity | 2013 |
| Description | Genetic discoveries pinpoint new causes for Alzheimer's disease |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Alzheimer's Society, Wales Regional Conference 14th July 2011 - Invited speaker Unknown |
| Year(s) Of Engagement Activity | 2011 |
| Description | Genetic modifiers workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Progress in neurodegenerative disorders Unknown |
| Year(s) Of Engagement Activity | 2011 |
| Description | Genetics of Alzheimer's Disease and its translation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Neurodem Research Development Group presentation on Genetics of Alzheimer's Disease unknown |
| Year(s) Of Engagement Activity | 2012 |
| Description | Genome wide association study of Alzheimer's disease |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Health professionals |
| Results and Impact | Invited Plenary - International Conference on Alzheimer's disease (ICAD) - Vienna - July 2009 Unknown |
| Year(s) Of Engagement Activity | 2009 |
| Description | Global media coverage |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | In September 2009 we published evidence of two new genes which are associated with susceptibility to Alzheimer's disease. This research generated substantial media interest both nationally and internationally. To see the BBC coverage of this story please visit: http://news.bbc.co.uk/1/hi/wales/8239773.stm. The story was covered in over 70 high quality publications (a full list is provided at the bottom this text). In addition, these findings have recently been recognised as one of the world's top 10 scientific breakthroughs of 2009 by Time magazine. See: http://www.time.com/time/specials/packages/article/0,28804,1945379_1944376_1944408,00.html Publications: Sky News Channel 4 News BBC Wales News ITV Wales Pittsburgh post - Gazette Daily Express Swansea Sound Washington Post New York Times Daily Telegraph Western Mail South Wales Echo The Independent The Irish Times Financial Times Sydney Morning Herald Ottawa Citizen Daily Mail Guardian The Mirror Nottingham Journal The Money Times The Sun Sindh Today Science Daily Belfast Telegraph Emax Health Malaysia News net Digital Journal Cambridge News Online Alzheimer's Society Real Radio Red Dragon Boston Globe Calgary Sun Norwich Evening News The Gov Monitor The Spokesman Review Food consumer Times of India Science News Medical News Today Top News NHS News Nature.com Blog Efitness.now Merinews Science Alert Pulse Today AHN Richmond Times - Dispatch The Birmingham News, Alabama Newsday, Melville NY The San Diego Union - Tribune, California El Nuevo Herald The Daily Gazette, New York St Paul's Pioneer Press Valley News Dispatch Chattanooga Times Free Press St Petersburg Times The Virginian - Pilot The Providence Journal The Gainsville Sun San Jose Mercury News The Journal Gazette Daily Times - Call The Tribune Visit Bulgaria Australian Ageing Agenda The News - Enterprise Ethiopian Review The Times - Tribune, PA South Florida Sun Sentinel ABC7 St Charles County Business Record The St Louis Countian Such extensive media coverage has raised the profile of Alzheimer's disease and dementia research. Since the articles were published we have received numerous enquiries from members of the public wanting to contribute to our research. It has also promoted our own research nationally and internationally and we have developed collaborations as a direct result of this media coverage. |
| Year(s) Of Engagement Activity | 2009 |
| Description | Grandround presentation - NHS Cardiff Postgraduate Centre |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | Regional |
| Primary Audience | Health professionals |
| Results and Impact | Defining the genetic architecture for Alzheimer's Disease unknown |
| Year(s) Of Engagement Activity | 2011 |
| Description | Health and Care Research Wales Public Engagement talk 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Institute of Psychological Medicine and Clinical Neurosciences staff at Cardiff University School of Medicine were required to attend a one hour presentation on the importance of engaging with the public in scientific research. The aim was to give staff a greater appreciation of public involvement, and the benefits of this in research. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.healthandcareresearch.gov.wales/involving-the-public-in-your-research |
| Description | House of Commons presentation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Alzheimer's Disease - causes, research unknown |
| Year(s) Of Engagement Activity | 2012 |
| Description | House of Lords Lunch |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Lunch discussion at The House of Lords unknown |
| Year(s) Of Engagement Activity | 2012 |
| Description | ICAD, Paris |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Role of the Immune System and Inflammatory Response in the Aetiology of Alzheimer's Disease unknown |
| Year(s) Of Engagement Activity | 2011 |
| Description | ITV Wales interview |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Interview with James Crichton-Smith at ITV Wales - ITV Wales are running a piece on early onset Alzheimers. |
| Year(s) Of Engagement Activity | 2015 |
| Description | ITV Wales interview Dec. 2015 |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Interview with James Crichton-Smith at ITV Wales - ITV Wales are running a piece on early onset Alzheimers. |
| Year(s) Of Engagement Activity | 2015 |
| Description | ITV news interview |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | ITV news interview with Julie Williams discussing research and new funding. Increase in requests for information from individuals wishing to take part in research |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www.itv.com/news/wales/update/2014-04-03/cardiff-university-leads-new-global-alzheimers-resea... |
| Description | IWA's Agenda magazine |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Professor Julie Williams' Alzheimer's research is featured in the summer edition of IWA's Agenda magazine (Agenda, No 41 Agenda, Front Page and Pgs 48-49) Unknown |
| Year(s) Of Engagement Activity | 2010 |
| Description | Insurance United Against Dementia |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Supporters |
| Results and Impact | Alzheimer's Society Insurance United Against Dementia campaign dinner - aim to formally launch IUAD partners to senior figureheads from the insurance industry Used as an opportunity to thank existing IUAD partners and inspire potential partners to make a contribution. |
| Year(s) Of Engagement Activity | 2019 |
| Description | International Genomics of Alzheimer's Project |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | A group led by Professor Julie Williams, School of Medicine is one of four involved in the International Genomics of Alzheimer's Project - a collaboration formed to discover and map the genes that contribute to Alzheimer's disease. http://www.medicalnewstoday.com/articles/215425.php Unknown |
| Year(s) Of Engagement Activity | 2011 |
| Description | Interview for national news |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Interview on national TV which is broadcast worldwide describing set up of Cardiff Univ receiving funding to set up as a UK dementia centre |
| Year(s) Of Engagement Activity | 2018 |
| URL | http://www.bbc.co.uk/news/uk-wales-south-east-wales-39646667 |
| Description | Interview for national news |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Official opening of UK DRI Cardiff, attended by 300+ guests, including funders, Welsh government officials, members of the public taking part in dementia research studies, postgraduates. Widely publicised on national BBC and ITV news and radio |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.bbc.co.uk/news/uk-wales-45942094 |
| Description | Interview for regional news |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Interview on regional news to discuss setting up of new DRI UK laboratories in Cardiff and work on dementia research |
| Year(s) Of Engagement Activity | 2018 |
| URL | http://www.itv.com/news/wales/2017-04-20/dementia-centre-to-offer-step-change-in-research/ |
| Description | Interview with ITV news |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Julie Williams was interviewed by ITV news in the HEB labs regarding Alzheimer's disease research |
| Year(s) Of Engagement Activity | 2015 |
| Description | It is time to make mental health research a funding priority |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Professor Julie Williams, School of Medicine, argues in an essay that it is time to make mental health research a funding priority. Cardiff University has committed to this in creating the new Neuroscience and Mental Health Research Institute - and Professor Williams calls on other decision makers and funders to do likewise. (W.Mail, 9.8.10 p26) Unknown |
| Year(s) Of Engagement Activity | 2010 |
| Description | Keynote speech Sutcliffe Kerr Lecture |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | Keynote speech at annual Walton Centre, Sutcliffe Kerr Lecture |
| Year(s) Of Engagement Activity | 2019 |
| Description | Kings College London Seminar |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Health professionals |
| Results and Impact | Delivered talk entitled - Psychiatric Genetics: Everything you always wanted to know but were afraid to ask Unknown |
| Year(s) Of Engagement Activity | 2010 |
| Description | Llandough Hospital |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Health professionals |
| Results and Impact | Dissemination of recent findings not known |
| Year(s) Of Engagement Activity | 2009 |
| Description | Local news item on brain donation for dementia research |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Older people in Wales are being urged to think about donating their brains after they die to help scientists researching dementia. This has sparked questions and debates - 80 comments within 24 hours. It will definitely influence people by raising awareness of the disease, the process of donation, benefits of donation/research and also opting in/out law change. We are confident this will increase the number of healthy/diseased donations and positively impact research field. |
| Year(s) Of Engagement Activity | 2018 |
| URL | http://www.bbc.co.uk/news/uk-wales-43084710 |
| Description | MRC CNGG celebration event |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | MRC CNGG celebration - presentation and video |
| Year(s) Of Engagement Activity | 2019 |
| Description | MRC CNGG/NCMH/CADR stand at the Wales Gene park's Genetics and Genomics Conference |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Representatives from the Alzheimer's Genetics Team manned a stand at the Wales Gene Park's Genetics and Genomics Conference on 22nd June, 2016. A number of individuals were interested in discussing the research environment, and how participants could help with discovery science. |
| Year(s) Of Engagement Activity | 2016 |
| URL | https://www.eventbrite.co.uk/e/genetics-and-genomics-for-the-3rd-generation-tickets-24871582573 |
| Description | Marshall Scholars |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | A talk entitled "New genetic findings in Alzheimers Disease" was presented to a group of Marshall Scholars not known |
| Year(s) Of Engagement Activity | 2010 |
| Description | Medical Women's Federation Spring Conference 2018 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation on 'Finding the causes of Alzheimer's disease' |
| Year(s) Of Engagement Activity | 2018 |
| Description | NGFN Symposium - Bonn |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Health professionals |
| Results and Impact | Delivered talk entitled - Molecular Genetics in Alzheimer's Dementia Unknown |
| Year(s) Of Engagement Activity | 2010 |
| Description | New Alzheimer's genes revealed |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Two potentially key genes linked to the development of Alzheimer's disease have been uncovered by UK researchers. Covered by major news channels including the BBC Nationwide media coverage will lead to increased public knowledge |
| Year(s) Of Engagement Activity | 2010 |
| Description | New Alzheimer's risk genes discovered in record study |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | A press release was issued highlighting the discovery of 11 new susceptibility genes for AD by the IGAP consortium. Details of these findings were published by all of the main UK news organisations. |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://www.cardiff.ac.uk/news/articles/new-alzheimers-risk-genes-discovered-in-record-study-11975.ht... |
| Description | New breakthrough in Alzheimer's research |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Professor Julie Williams, School of Medicine, comments on a new breakthrough in Alzheimer's research which has seen scientists unravel the precise function of genes known to make people more at risk of developing the illness. (Daily Express, 28.10.11, p.17) Unknown |
| Year(s) Of Engagement Activity | 2011 |
| Description | New susceptibility genes for Alzheimer's disease |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Health professionals |
| Results and Impact | Invited speaker - Eisai Symposium in Neuroscience (Dementia and Cognitive Dysfunction) - May 2010 Unknown |
| Year(s) Of Engagement Activity | 2010 |
| Description | Oxford Seminar Series |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Health professionals |
| Results and Impact | Invited speaker - Seminar Series,University of Oxford - June 2010 Unknown |
| Year(s) Of Engagement Activity | 2010 |
| Description | Plenary Speaker at the Alzheimer's Association International Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The plenary speech described our scientific advances in gene discovery and AD risk prediction. This reached an audience of several thousand researchers, clinicians, families, policy makers and funders in the dementia area. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Pratchett play for Alzheimer's |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | A researcher at Cardiff University's National Centre for Mental Health has produced a play adapted from a Terry Pratchett novel in a bid to raise money for Alzheimer's Research UK. Unknown |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://www.cardiff.ac.uk/news/articles/pratchett-play-for-alzheimers-11246.html |
| Description | Presentation and Questions at Carers Group. Participant = Alun Meggy (AD Team) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Carers attend weekly groups that cover a variety or topics about dementia. We were invited to talk about research. The group organiser asked for a further talk in the future |
| Year(s) Of Engagement Activity | 2017 |
| Description | Presentation and Questions at Torfaen Carers Centre. Participants = Alun Meggy, Jack Beaumont (AD Team) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Study participants or study members |
| Results and Impact | People with dementia and their carers/ families attended a talk to understand why research is important in the field of dementia |
| Year(s) Of Engagement Activity | 2017 |
| Description | Probus Cardiff |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Provided a talk at the Combined Probus Club of Cardiff Inc. Increased public awareness of Alzheimer's research |
| Year(s) Of Engagement Activity | 2012 |
| Description | Public Meeting |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | Yes |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | We hosted a public meeting, supported by the Alzheimer's Research Trust, in September 2007. In addition to events hosted within the University we have also presented our research findings to carers, and individuals with AD at Alzheimer's Society regional meetings in Cardiff, Swansea, Blackwood and Caerleon and to the members of the Newport Carers Group and County Hosptial Carers Group, Pontypool. These meetings contribute substantially to engaging the public in our research. |
| Year(s) Of Engagement Activity | 2007 |
| Description | Quote for This is Wales publication |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Quotation provided on the subject of innovation in Wales for trade magazine, emphasising research focus on dementia, specifically Alzheimer's disease |
| Year(s) Of Engagement Activity | 2018 |
| Description | RCPsych Neuropsychiatry Annual Conference 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Talk given to conference entitled "Neuropsychiatric Genetics of Dementia and other Neurodegenerative Disorders: Implications for treatment, prevention and personalised psychiatry" |
| Year(s) Of Engagement Activity | 2019 |
| Description | Radio Cymru Discussion on Alzheimer's disease. Participant = Alun Meggy, AD Team |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Mr Alun Meggy took part in a Welsh discussion group broadcast live on Radio Cymru on 17th February 2017. Alun spoke in Welsh regarding Alzhiemer's disease research, and how we are working hard to develop our knowledge of this debilitating disease. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Radio Interview with Alz Res UK Champion |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Radio Gloucester interview with Sue Strachan Alz Res UK Champion |
| Year(s) Of Engagement Activity | 2021 |
| Description | Radio discussion |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | Regional |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | BBC Radio Wales Jason Mohammed show discussing progress in Alzheimer's Disease Research unknown |
| Year(s) Of Engagement Activity | 2012 |
| Description | Recorded interview ARUK conference March 2018 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | An interview with Video Journal Dementia at ARUK Conference 2018 discussing work at Cardiff DRI UK - online publication aimed at healthcare professionals |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://vjdementia.com/speaker/julie-williams |
| Description | Researchers Find Two More Genetic Risk Factors For Alzheimer's Disease |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Widespread worldwide broadcast, press and online coverage of a major new study into Alzheimer's led by researchers at Cardiff University. Including BBC, Channel 4, SKY and ABC news, The Telegraph, The Times, The Telegraph, The New York Times and all over major news channels / papers. "The MRC Centre and research like this is changing our understanding of what causes the common form of Alzheimer's disease and provides valuable new leads in the race to find treatments and possibly cures. "It also shows that other genes can be identified using this method, and we are already planning a larger study involving 60,000 people, which can be achieved within the next year. "It is also important to recognise the contribution many Welsh people who have acted as subjects for this research over the years." |
| Year(s) Of Engagement Activity | 2009,2010 |
| Description | Rugby legend's research donation |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | A Wales and British Lions rugby legend will help boost the University's world-leading Alzheimer's research by chipping-in with a charity donation. Charitable donation received |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://www.cardiff.ac.uk/news/articles/rugby-legends-research-donation-9461.html |
| Description | SciScreen Dementia Event |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Dr Rebecca Sims gave a public presentation on Dementia research before a free screening of the film "Away from Her", post-film discussion and free drinks reception. The purpose of the event is for scientists to engage with the general public for mutual benefit. The presentation was well received, and the discussions were lively. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Science Cafe talk 10th May 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | A talk was given by PhD student and Neurologist, Dr Jude Harrison. Science Cafe events are designed to encourage the general public to engage with science in an informal environment. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Scientists at Cardiff University say they are a step closer to understanding the causes of dementia |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Scientists at Cardiff University say they are a step closer to understanding the causes of dementia, thanks to a grant of nearly £250,000. The money will fund its brain bank, a centre which encourages people to donate their brains for medical research. Professor Julie Williams comments (BBC Wales On-line, 04.07.2013 Unknown |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://www.bbc.co.uk/news/uk-wales-22288025 |
| Description | Seven preventable risk factors which can be attributed to Alzheimer's disease |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Professor Julie Williams, School of Medicine, comments on a new study by scientists in the US which shows seven preventable risk factors which can be attributed to Alzheimer's disease. (Western Mail, 20.07.11, p.10); (South Wales Echo, 20.07.11, p.20) Unknown |
| Year(s) Of Engagement Activity | 2011 |
| Description | Taking a new look at the risk factors for Alzheimer's disease |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Media article on publication of Multiplex Model in Nature Neuroscience - providing information on how the genes that have been identified as risk factors impact on other genes to trigger Alzheimer's |
| Year(s) Of Engagement Activity | 2020 |
| Description | Tenby Observer |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Talk by Prof Julie Williams (at Oriel y Parc, 5 Aug) advertised |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.tenby-today.co.uk/article.cfm?id=105748&headline=Oriel%20y%20Parc%20to%20host%20second%20... |
| Description | The Academy of Medical Sciences, Cardiff |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Successful collaborations with basic scientists unknown |
| Year(s) Of Engagement Activity | 2011 |
| Description | The Alzheimer's Society first all-Wales conference in Swansea |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Professor Julie Williams, School of Medicine, was a keynote speaker on the genetic causes of Alzheimer's at the Alzheimer's Society first all-Wales conference in Swansea. (W.Mail 12.7.11 p12) Unknown |
| Year(s) Of Engagement Activity | 2011 |
| Description | The First Minister for Wales Carwyn Jones has appointed Cardiff University's Professor Julie Williams, School of Medicine, as Wales' Chief Scientific Adviser. |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | The First Minister for Wales Carwyn Jones has appointed Cardiff University's Professor Julie Williams, School of Medicine, as Wales' Chief Scientific Adviser. Unknown |
| Year(s) Of Engagement Activity | 2013 |
| Description | The International Genomics of Alzheimer's Project (IGAP) |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | A leading University expert in identifying genes that cause Alzheimer's disease will meet with some of the world's other figures for the first-time in Paris (Friday 19th November) in a bid help share knowledge and speed-up the genetic fight against the disease. The International Genomics of Alzheimer's Project (IGAP) is a major international consortium which brings together for the first time four of the world's leading research centres - including Professor Julie Williams, School of Medicine, who leads the Genetic and Environmental Risk in Alzheimer's Disease (GERAD). Unknown |
| Year(s) Of Engagement Activity | 2010 |
| Description | The International Genomics of Alzheimer's Project (IGAP) |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | The International Genomics of Alzheimer's Project (IGAP) - a group of leading experts in Alzheimer's research from Europe, USA and the rest of the world has been established. The new international group includes Professor Julie Williams, School of Medicine (PR Newswire, 01.02.11, www.prnewswire.com/news-releases/first-international-collaboration-on-the-genetics-of-alzheimers-disease-is-launched-114989074.html) Unknown |
| Year(s) Of Engagement Activity | 2011 |
| Description | The Today Programme |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | JW on BBC Radio 4's Today programme talking about her discovery of two new genes associated with Alzheimer's disease which could provide valuable new leads in the race to find treatments and possibly cures for the devastating condition Unknown |
| Year(s) Of Engagement Activity | 2009 |
| Description | Time Magazine - Medical breakthroughs of 2009 |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | A key University study which helped uncover two new genes associated with Alzheimer's disease has been recognised as one of the top 10 medical breakthroughs of 2009 by TIME Magazine. International acknowledgement of research findings. |
| Year(s) Of Engagement Activity | 2009 |
| Description | U3A Brecon |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Participants in your research and patient groups |
| Results and Impact | Dissemination of Alzheimers research findings not known |
| Year(s) Of Engagement Activity | 2010 |
| Description | UK Korea Neuroscience Symposium |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | UKorea symposia bridge basic and clinical research within neuroscience. J Williams gave plenary lecture on 1st day 2019 symposium. The statements were shared via the UK-Korea social media channel (twitter @UKorea_Neuro). |
| Year(s) Of Engagement Activity | 2019 |
| Description | UN Older Persons Day - Cardiff |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Delivered talk entitled - Will identifying susceptibility genes for Alzheimer's Disease increase healthy aging? Unknown |
| Year(s) Of Engagement Activity | 2010 |
| Description | US Fulbright Scholars Forum |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | International |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | Spoke at the US Fulbright Scholars Forum . Each year the Fulbright Awards team organise a week-long Forum for current US postgraduates and scholars to get together and explore a different part of the country. This January, over fifty grantees descended on the cities of Bristol and Cardiff to explore Wales and the West Country. Fulbright was generously hosted by the University of Bristol and the University of Cardiff who helped put on an excellent series of events. Unknown |
| Year(s) Of Engagement Activity | 2013 |
| URL | https://www.bfsa.org/wales |
| Description | Un o Bob Tri (One of Every Three) Television Programme for S4C |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | Regional |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Interview for TV programme http://www.s4c.co.uk/ffeithiol/e_un_bob_tri.shtml unknown |
| Year(s) Of Engagement Activity | 2012 |
| Description | University's work on Alzheimer's |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Professor Julie Williams, School of Medicine, discusses the University's work on Alzheimer's. (BBC Radio Wales 17.2.11) Unknown |
| Year(s) Of Engagement Activity | 2011 |
| Description | Update on medical and scientific advances in prevention and treatment of dementia |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Health professionals |
| Results and Impact | UK dementia Congress Plenary: Update on medical and scientific advances in previention and treatment of dementia unknown |
| Year(s) Of Engagement Activity | 2012 |
| Description | Visit to DRI laboratories by Sir Venki Ramakrishnan |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | Sir Venki Ramakrishnan, the President of the Royal Society visited DRI laboratories, Cardiff on 23rd October prior to giving a lecture organised by Welsh Government |
| Year(s) Of Engagement Activity | 2019 |
| Description | WAG Seminar |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Presented recent research findings to policy makers not known |
| Year(s) Of Engagement Activity | 2010 |
| Description | Wales Gene Park 10th Anniversary, Cardiff "Defining the genetic architecture of Alzheimer's disease" |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Provided a talk entitled "Defining the Genetic Architecture of Alzheimer's Disease" Unknown |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://www.walesgenepark.cardiff.ac.uk/wp-content/uploads/2013/04/4_Julie_Williams.pdf |
| Description | Welsh Government workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | The Welsh Government held a UKRI "Strength in Places Fund" and potential for Wales workshop. Strength in Places (SIP) offers a significant funding opportunity and the University is keen to prepare a pipeline of projects for development in this area, in what is anticipated, to be an annual call. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Welsh language champions in NHS health boards |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Professor Julie Williams, School of Medicine comments on plans to appoint Welsh language champions in NHS health boards. (Western Mail, 7/6/10, p25) Unknown |
| Year(s) Of Engagement Activity | 2010 |
| Description | Welsh presentation (Cardiff Science Society) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | A presentation was given in Welsh, by Alzheimer's Field Worker, Alun Meggy to the Cardiff Science Society on 21st November 2016. This was followed by questions and a discussion. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.cymdeithaswyddonolcaerdydd.org |
| Description | Western Mail/ Wales online interview |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | An article was published online and in print not known |
| Year(s) Of Engagement Activity | 2012 |
| URL | http://www.walesonline.co.uk/lifestyle/showbiz/how-professor-julie-williams-went-2017479 |
| Description | Westminster visit - Dementia |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Dissemination of research findings to parliamentarians not known |
| Year(s) Of Engagement Activity | 2009 |
| Description | Will identifying susceptibility genes for Alzheimer's disease increase healthy ageing? |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Invited speaker - United Nations Older Person's Day - Promoting active and healthy ageing - Cardiff, 30th September 2010 Unknown |
| Year(s) Of Engagement Activity | 2010 |
| Description | Will members of my family develop Alzheimers disease?' |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Dr Rebecca Sims presented "Will members of my family develop Alzheimer's disease?" at CADR Meeting Swansea, 2/8/2018. This reached an audience of 50 persons including general public, medical professionals, researchers and carers. This generated a number of questions and discussion after the talk, and was part of a wider discussion following other presentations focusing on similar topics. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Women in Industry |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Industry/Business |
| Results and Impact | Presentation to Women in Industry event, providing overview of career, advice for women in STEM careers |
| Year(s) Of Engagement Activity | 2019 |
| Description | Women in Science film |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Women in Science video as one of the interviewees / case studies. |
| Year(s) Of Engagement Activity | 2019 |
| Description | World Dementia Conference - speaker |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | This WDC summit meeting was focused on 'Looking to the Future: The Dementia landscape' and followed the series of global dialogues as part of the WDC's dementia landscape project. Discussion took place on the science and research agenda and built on previous conversations of international dementia leaders around innovation and incentives and data sharing. As a guest speaker, asking the question 'are we on track', we explored whether the research and policy landscape facilitating the development of new treatments required global co-ordination, considered whether the right things are being funded and whether new funding models were required. |
| Year(s) Of Engagement Activity | 2021 |
| Description | Young Onset Dementia: Different impact, positive solutions conference |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | This public meeting was held on 27th September, 2016. This was a recruitment opportunity. |
| Year(s) Of Engagement Activity | 2016 |
| URL | https://www.youngdementiauk.org/sites/default/files/Young%20Dementia%202016%20programme.pdf |
| Description | Zeurs Austria - Drugs Genetics |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Presented talk entitled - Defining the genetic architecture for AD not known |
| Year(s) Of Engagement Activity | 2009 |
| Description | alt.Cardiff blog entry |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Journalist Jessica Phillips interviews Julie Williams for an article on her blog |
| Year(s) Of Engagement Activity | 2015 |
| Description | the country needs more scientists |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Wales' new chief scientific adviser, Prof Julie Williams, says the country needs more scientists. The Merthyr-born academic was appointed a CBE for her Alzheimer's research at the School of Medicine in Cardiff, and her appointment was announced last month (BBC Wales Today; BBC Wales On-line, 16.09.2013 Unknown |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://www.bbc.co.uk/news/uk-wales-24111210#?utm_source=twitterfeed&utm_medium=twitter |